AlloVir to wind down PhIII trials for futility and will review strategic alternatives
26 Dec 2023
Phase 3Cell TherapyImmunotherapy
AlloVir is pondering its corporate future after finding out that its lead antiviral cell therapy candidate is likely ineffective.
The biotech had been testing posoleucel, an off-the-shelf virus-specific T cell therapy, in three separate Phase III trials. At the pre-planned futility analyses, all three independent data safety monitoring boards (DSMBs) recommended stopping the respective trials they were overseeing, all saying that data suggested the studies were unlikely to meet their primary endpoints.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.